Moderna Stock Phase 2

It s possible that moderna s stock fell on may 26 news that a rival novavax had enrolled its first participants in a phase 1 2 trial of its covid 19 vaccine candidate.

Moderna stock phase 2. The move puts t he biotech. Mrna a clinical stage biotechnology company pioneering messenger rna mrna therapeutics and vaccines to create a new generation of transformative medicines for patients today announced that it has completed enrollment for both cohorts of the phase 2 study of its vaccine candidate mrna 1273 against covid 19. The imminent phase 2 study start is a crucial step forward as we continue to advance the clinical development of mrna 1273 our vaccine candidate against sars cov 2. Mrna said monday that it has submitted an investigational new drug application to the fda seeking the regulatory agency s consent to proceed with phase 2 and late stage.

With phase 3 clinical trial data also showing mrna 1273 to be generally well tolerated among the study s 30 000 participants. Moderna s cytomegalovirus cmv vaccine which is currently in phase 2 studies and could move to phase 3 in 2021 is likely to be the company s first candidate for approval after its covid 19. Moderna nasdaq mrna stock has rallied by almost 15 over the past month as the company continues with its phase 3 clinical trials with late stage clinical data. 8 2020 moderna inc nasdaq.

As of 2 p m. Moderna nasdaq mrna has enrolled the first participants in a phase 2 clinical trial testing mrna 1273 its vaccine against the novel coronavirus that causes covid 19.